• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Comment

Mød ledelsen i Gubra og stil spørgsmål til dagens investorpræsentation

By Victor SkriverEquity Research Assistant
Gubra

Her til eftermiddag kl. 13.00 vil Gubras CFO Kristian Borbos og IR and Strategy Lead Emma Jappe Lange præsentere Q1 2026 handelsopdateringen og svare på spørgsmål fra publikum. Tilmeld dig og stil dine spørgsmål allerede nu: https://www.inderes.dk/videos/gubra-praesentation-af-q1-2026-handelsopdatering

Disclaimer: HC Andersen Capital modtager betaling fra det nævnte selskab for en digital IR abonnementsaftale. /Victor Skriver d. 12/05-2026 kl. 08:30.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more on company page